Skip to main content

Advertisement

Log in

Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the immediate and short-term effects of intravitreal injection of 1.25 mg/0.05 ml of bevacizumab on intraocular pressure related to different ocular axial lengths.

Design

A prospective case series of consecutive patients referred to the Department of Ophthalmology, San Pietro-Fatebenefratelli Hospital, from September 2011 through January 2011.

Methods

Twenty-five patients (10 men and 15 women, mean age 70.2 ± 8.98 years) scheduled for intravitreal injection of bevacizumab for the treatment of neovascular age-related macular degeneration were enrolled in this study. Axial length was measured preoperatively using IOLMaster. Intraocular pressure was measured before injection, after 1 min and after 15 min using Tono-Pen XL tonometry.

Results

The mean intraocular pressure change following the intravitreal bevacizumab injection was 21.92 ± 6.95 mmHg after 1 min and 6.24 ± 3.77 mmHg after 15 min. The mean axial length of the examined eyes was 23.2 ± 1.06 mm. A good correlation was observed between the axial length and intraocular pressure rise after both 1 (R 2 = 0.752, p < 0.001) and 15 min (R 2 = 0.559, p < 0.001).

Conclusions

Patients undergoing intravitreal injection of 0.05 ml of bevacizumab can be exposed to intraocular pressure increases correlated to ocular axial length.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–9.

    PubMed  CAS  Google Scholar 

  2. Rl Avery, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–72.

    Article  Google Scholar 

  3. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularisation in pathologic myopia. Retina. 2006;26:1093–4.

    Article  PubMed  Google Scholar 

  4. Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85:777–81.

    Article  PubMed  Google Scholar 

  5. Frenkel REP, Mani L, Toler AR, Frenkel MPC. Intraocular pressure effects of Pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034–5.

    Article  PubMed  CAS  Google Scholar 

  6. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009;23:181–5.

    Article  PubMed  CAS  Google Scholar 

  7. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930–4.

    Article  PubMed  CAS  Google Scholar 

  8. Wu H, Chen TC. The effects of intravitreal ophthalmic medications on intraocular pressure. Semin Ophthalmol. 2009;24:100–5.

    Article  PubMed  Google Scholar 

  9. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27:1044–7.

    Article  PubMed  Google Scholar 

  10. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42:807–11.

    Article  PubMed  Google Scholar 

  11. Utman SA, Dhillon B. Comment on: changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2008;28:667.

    Article  PubMed  Google Scholar 

  12. Tsui YP, Chiang CC, Tsai YY. Paracentesis before intravitreal injection of bevacizumab. Can J Ophthalmol. 2008;43:239.

    Article  PubMed  Google Scholar 

  13. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arc Ophthalmol. 2010;128:1523–7.

    Google Scholar 

  14. Kim KS, Jee D. Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique. Jpn J Ophthalmol. 2011;55:632–7.

    Article  PubMed  Google Scholar 

  15. Ueda T, Nawa Y, Hara Y. Relationship between the retinal thickness of the macula and the difference in axial length. Graefes Arch Clin Exp Ophthalmol. 2006;244:498–501.

    Article  PubMed  Google Scholar 

  16. Kojima T, Tamaoki A, Yoshida N, Kaga T, Suto C, Ichikawa K. Evaluation of axial length measurement of the eye using partial coherence interferometry and ultrasound in cases of macular disease. Ophthalmology. 2010;117:1750–4.

    Article  PubMed  Google Scholar 

  17. Guidelines for performing intravitreal therapy. The Royal Australian and New Zealand College of Ophthalmologists. 2006.

  18. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusin P. Short-term effect of intravitreal injection of ranibizumab (lucentis) on intraocular pressure. J Glaucoma. 2009;18:658–61.

    Article  PubMed  Google Scholar 

  19. Boon CJF, Crama N, Klevering BJ, van Kuijk FJ, Hoyng CB. Reflux after intravitreal injection of bevacizumab. Ophthalmology. 2008;115:1270.

    Article  PubMed  Google Scholar 

  20. Pallikaris IG, Kymionis GD, Ginis HS, Kounis GA, Tsilimbaris MK. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci. 2005;45:409–14.

    Article  Google Scholar 

  21. Pallikaris IG, Kymionis GD, Ginis SH, Kounis GA, Christodoulakis E, Tsilimbaris MK. Ocular rigidity in patients with age related macular degeneration. Am J Ophthalmol. 2006;141:611–5.

    Article  PubMed  Google Scholar 

  22. Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol. 2011;89:138–42.

    Article  PubMed  Google Scholar 

Download references

Ethical standard

The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local Ethics Committee. Each patient signed an informed consent before enrollment.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fabio Scarinci.

About this article

Cite this article

Cacciamani, A., Oddone, F., Parravano, M. et al. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 57, 63–67 (2013). https://doi.org/10.1007/s10384-012-0194-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-012-0194-8

Keywords

Navigation